<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390595</url>
  </required_header>
  <id_info>
    <org_study_id>MS100070_0160</org_study_id>
    <secondary_id>2017-004260-36</secondary_id>
    <nct_id>NCT03390595</nct_id>
  </id_info>
  <brief_title>Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma</brief_title>
  <official_title>Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associació per a la Recerca Oncologica, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck, S.L., Spain</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associació per a la Recerca Oncologica, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Multicentre, randomized, open-label study to evaluate the safety and efficacy of
      avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with
      unresectable or metastatic urothelial carcinoma (UC) who have not received prior systemic
      therapy and who are ineligible to receive cisplatin-based therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate if the response rates (complete response [CR] + partial
      response [PR]) are sufficiently high and the severe acute toxicity rates acceptably low.
      Patients must be cisplatin-ineligible as defined by consensus criteria (see Inclusion
      criteria). Patients who experience disease progression &gt;12 months following completion of a
      platinum-based adjuvant or neoadjuvant regimen will also be eligible for enrolment into the
      study.

      Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the
      informed consent form, they will be randomized in a 1:1 ratio to receive avelumab in
      combination with gemcitabine/carboplatin or gemcitabine/carboplatin alone as follows:

        -  Arm A: patients will receive 2 cycles of induction avelumab 10mg/kg every 2 weeks
           followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1,
           gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed
           by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.

        -  Arm B: patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day
           +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.

      Random assignment of treatment will be stratified by the presence or absence of visceral
      metastasis and ECOG &lt; 2 versus ECOG 2.

      All the patients enrolled in avelumab arm will receive avelumab monotherapy maintenance until
      disease progression or intolerable/unacceptable toxicity. Patients in the
      carboplatin-gemcitabine arm, will receive up to six cycles of treatment. Tumour evaluations
      will be scheduled every 6 weeks (±2 weeks) during carboplatin-gemcitabine treatment (in case
      of cycle delay this tumour evaluations every 6 weeks should be maintained to avoid any bias
      in the assessment of date of progression with appropriate imaging studies for response
      evaluation) and every 9 weeks thereafter until progressive disease (during this period,
      patients at arm A will be receiving avelumab maintenance treatment).

      Patients with disease progression during the treatment phase will be withdrawn from the study
      and will receive their treatment according to the investigator's judgment and monitored to
      evaluate OS.

      If a patient withdraws consent and refuses to receive more treatment, the patient must be
      followed up for survival. If a patient withdraws consent and refuses to continue in the
      study, the follow-up evaluations must be discontinued.

      If at the moment of end of study there would be any patient still on maintenance treatment
      with avelumab, Sponsor will have commitment to provide the study drug in case patient is
      having clinical benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>The ORR is defined as the sum of the complete and partial responses (CR+PR), (according to Response Evaluation Criteria in Solid Tumours [RECIST criteria v1.1] and irRECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomisation to either documented disease progression or death from any cause (whichever occurs earlier).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomisation to death from any cause. Patients still alive at the time of OS analysis will be censored on their last date of contact. Patients who withdraw from the study without having completed the withdrawal consent will be followed up to determine their status whenever possible.
For the purposes of this study, subjects should be evaluated every 6 weeks with the appropriate imaging technique according to each centre's routine practice, during the combined treatment, and every 9 weeks during the maintenance period. In case of cycle delay every 6 weeks should be maintained to avoid any bias in the assessment of the date of progression with the appropriate imaging studies for response evaluation. Response will be monitored as per the RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the first confirmation of objective response according to RECIST 1.1 criteria until disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of adverse events. AEs will be coded and evaluated using the National Cancer Institute, Common Toxicity criteria for Adverse Events (NCI-CTCAE) v4.03 toxicity criteria (if NCI-CTCAE are not applicable, the Medical Dictionary for Regulatory Activities [MedDRA] will be used).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of pathologic resistance mechanisms to treatment combination</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of resistance mechanisms in disease's biopsies, describing the pathologic features that may predict response or resistance to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of immunologic resistance mechanisms to treatment combination</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of resistance mechanisms in blood serum, describing the immunologic features that may predict response or resistance to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of genomic resistance mechanisms to treatment combination</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of PD-L1 expression in tumor infiltrating immune cells and in tumor cells (pre and post-treatment samples will be analyzed).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Avelumab plus gemcitabine/carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine/carboplatin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>avelumab 10mg/kg with carboplatin/gemcitabine</intervention_name>
    <description>Dosage and schedule:
Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:
Intravenously every 2 weeks for two cycles.
During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.
Intravenously every 2 weeks until progressive disease or intolerance.
Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC
Carboplatin 5AUC day +1.
Gemcitabine 1000mg/m2 day +1 and +8.</description>
    <arm_group_label>Avelumab plus gemcitabine/carboplatin</arm_group_label>
    <other_name>Bavencio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>carboplatin/gemcitabine alone</intervention_name>
    <description>•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC
Carboplatin 5AUC day +1.
Gemcitabine 1000mg/m2 day +1 and +8.</description>
    <arm_group_label>Gemcitabine/carboplatin alone</arm_group_label>
    <other_name>Standard of care for UC treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient has given written informed consent stating that he or she understands the
             purpose of the study and the procedures involved and agrees to participate in the
             study.

          2. The patient has histologically confirmed unresectable UC (T4b, any N; or any T, N2-3)
             or metastatic (M1, Stage IV) UC of the urinary tract, including renal pelvis, ureters,
             urinary bladder, and urethra

          3. No prior systemic therapy for inoperable locally advanced or metastatic UC. For
             patients who received prior adjuvant/neoadjuvant chemotherapy or chemo radiation for
             UC, a treatment-free interval &gt;12 months between the last treatment administration and
             the date of recurrence is required in order to be considered treatment naive in the
             metastatic setting.

          4. Ineligible (&quot;unfit&quot;) for cisplatin-based chemotherapy as defined by any one of the
             following criteria:

               1. Impaired renal function (GFR &lt;60 mL/min)

               2. ECOG performance status of 2

               3. New York Heart Association Class III hear failure

               4. Grade ≥2 hearing loss (measured by audiometry) or ≥25 dB at two contiguous
                  frequencies

               5. Grade ≥2 peripheral neuropathy * Criteria 4a and b are mutually exclusive: those
                  patients with ECOG 2 won't be allowed to have an impaired renal function. For
                  rest of the criteria, several of them may coexist.

          5. The patient has at least one measurable tumour lesion (measurable disease, as defined
             by the RECIST criteria v1.1). If all sites of measurable disease have been irradiated,
             one site must have demonstrated growth after irradiation.

          6. Age ≥18 years.

          7. ECOG PS 0-2.

          8. Life expectancy of at least 12 weeks.

          9. Adequate hematologic, hepatic, and renal function, defined by:

               1. Platelet count ≥100 x109/L.

               2. Hemoglobin ≥ 9 g/dL (may have been transfused).

               3. Absolute neutrophil count (ANC) ≥1.5x109/L.

               4. Serum creatinine ≤1.5 times the upper limit of normality (ULN). If creatinine 1.0
                  1.5 xULN, creatinine clearance will be calculated according to Chronic Kidney
                  Disease Epidemiology group (CKD-EPI) formula and patients with creatinine
                  clearance &lt;50 mL/min should be excluded.

                  NOTE: The CKD-EPI formula for creatinine clearance is as follows:

                  GFR = 141 x min(Scr/κ,1)^α x max(Scr/κ,1)^-1.209 x 0.993^Age x 1.018 [if female]
                  x 1.159 [if black].

                  Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α
                  is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or
                  1, and max indicates the maximum of Scr/κ or 1. See Appendix VII for details.

                  Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault
                  formula (or local institutional standard method)

               5. Alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT) and
                  alkaline phosphatase (AP) ≤2.5 ×ULN (≤5 ×ULN in the presence of liver
                  metastasis), and serum total bilirubin ≤1.5 ×ULN.

         10. Free T4 and TSH within normal range.

         11. Archival or newly-obtained representative formalin-fixed paraffin-embedded (FFPE)
             tumor specimens in paraffin blocks must be available.

         12. Females of childbearing potential must have a negative serum pregnancy test within 7
             days of study entry. Patients of childbearing potential who participate in this study
             must use effective contraceptive methods (e.g., abstinence, intrauterine device, oral
             or injectable contraceptives, a double barrier method or surgical sterility) to
             prevent pregnancy starting as soon as the informed consent form is signed and
             continuing for at least 13 weeks after the last dose of the study medication is
             administered. at least 30 days after last avelumab treatment administration if the
             risk of conception exists.

        Exclusion Criteria:

          1. Women who are currently pregnant or breast-feeding.

          2. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
             risk based on investigator's judgment are acceptable.

          3. Patients who had undergone major surgery, radiation therapy or treatment with
             chemotherapy or any investigational agent within 28 days prior to Study day 1.

          4. Evidence of severe or uncontrolled systemic disease or any concurrent condition
             (including uncontrolled diabetes mellitus) which in the Investigator's opinion makes
             it undesirable for the subject to participate in the study or which would jeopardize
             compliance with the protocol.

          5. History of another neoplasm. However, patients with prior history of either
             non-metastatic non melanoma skin cancers; carcinoma in situ of the cervix; or cancer
             cured by surgery, small field radiation or chemotherapy ≥3 years prior to
             randomisation; or treated patients with early stage and low risk prostate cancer (≤pT2
             N0 M0, Gleason ≤6 and Prostate-specific antigen [PSA] ≤0.5 ng/mL) at study entry will
             be eligible.

          6. Prior allogeneic stem cell or solid organ transplantation, or active autoimmune
             disease that might deteriorate when receiving an immuno-stimulatory agent. However,
             patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases
             not requiring immunosuppressive treatment are eligible

          7. Current use of immunosuppressive medication, EXCEPT for the following:

               1. Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,
                  intra-articular injection);

               2. Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or
                  equivalent;

               3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication).

          8. History of idiopathic pulmonary fibrosis.

          9. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular
             accident/stroke (&lt; 6 months prior to enrolment), myocardial infarction (&lt; 6 months
             prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart
             Association Classification Class II), or serious cardiac arrhythmia requiring
             medication.

         10. Known history of testing positive for HIV or known acquired immunodeficiency syndrome.

         11. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
             HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).

         12. Active tuberculosis.

         13. Active infection requiring systemic therapy.

         14. Vaccination within 4 weeks of the first dose of avelumab and while on trials is
             prohibited except for administration of inactivated vaccines.

         15. Known prior severe hypersensitivity to investigational product or any component in its
             formulations, including known severe hypersensitivity reactions to monoclonal
             antibodies (NCI CTCAE v4.03 Grade ≥ 3).

         16. Other severe acute or chronic medical conditions including colitis, inflammatory bowel
             disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent
             (within the past year) or active suicidal ideation or behaviour; or laboratory
             abnormalities that may increase the risk associated with study participation or study
             treatment administration or may interfere with the interpretation of study results
             and, in the judgment of the investigator, would make the patient inappropriate for
             entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquín Bellmunt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejo Rodríguez-Vida, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquín Bellmunt, MD, PhD</last_name>
    <phone>932 483 860</phone>
    <email>joaquim.bellmunt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inmaculada Musté</last_name>
    <phone>932 274 760</phone>
    <email>oncologia.apro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico José Vázquez, MD, PhD</last_name>
      <phone>+34 966 616 250</phone>
      <email>fvazquezmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Federico José Vázquez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología (ICO L'Hospitalet) - H. Durán i Reynals</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier García del Muro, MD, PhD</last_name>
      <phone>+34 932 607 332</phone>
      <email>garciadelmuro@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Xavier García del Muro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Althaia - Xarxa Assistencial Univ. de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Montserrat Domènech, MD, PhD</last_name>
      <phone>+34 938 75 93 00</phone>
      <email>mdomenech@althaia.cat</email>
    </contact>
    <investigator>
      <last_name>Montserrat Domènech, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Bonfill, MD, PhD</last_name>
      <phone>+34 935 537 134</phone>
      <email>tbonfill@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Teresa Bonfill, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Gallardo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Luís Pérez, MD, PhD</last_name>
      <phone>+34 948 25 54 00</phone>
      <email>jlgracia@unav.es</email>
    </contact>
    <investigator>
      <last_name>José Luís Pérez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo Rodríguez-Vida, MD, PhD</last_name>
      <phone>+34 932 483 139</phone>
      <email>arodriguezvida@hospitaldelmar.cat</email>
    </contact>
    <investigator>
      <last_name>Alejo Rodríguez-Vida, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Pablo Maroto, MD, PhD</last_name>
      <phone>+34 935 537 134</phone>
      <email>JMaroto@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>José Pablo Maroto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD, PhD</last_name>
      <phone>+34 934 89 30 00</phone>
      <email>rmorales@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Joan Carles Galceran, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clìnic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Begoña Mellado, MD, PhD</last_name>
      <phone>+34 93 227 54 02</phone>
      <email>BMELLADO@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Begoña Mellado, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Castellano, MD,PhD</last_name>
      <phone>+34 913 90 80 00</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Castellano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD, PhD</last_name>
      <phone>+34 913 30 30 01</phone>
      <email>jpuente.hcsc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Puente, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Álvaro Pinto, MD, PhD</last_name>
      <phone>+34 91 727 75 16</phone>
      <email>alvaropintomarin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Álvaro Pinto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrique González, MD, PhD</last_name>
      <phone>+34 968 360 900</phone>
      <phone_ext>3807</phone_ext>
      <email>enrique.gonzalezbilla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Enrique González, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Begoña Pérez, MD, PhD</last_name>
      <phone>+34 955 01 30 68</phone>
      <email>bperezv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Begoña Pérez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Ángel Climent, MD, PhD</last_name>
      <phone>+34 961 11 40 00</phone>
      <email>macliment@fivo.org</email>
    </contact>
    <investigator>
      <last_name>Miguel Ángel Climent, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://apro.org.es/</url>
    <description>APRO Website</description>
  </link>
  <reference>
    <citation>Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999 Oct;17(10):3173-81.</citation>
    <PMID>10506615</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.</citation>
    <PMID>21351269</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.</citation>
    <PMID>20116997</PMID>
  </reference>
  <reference>
    <citation>Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.</citation>
    <PMID>24373477</PMID>
  </reference>
  <reference>
    <citation>AJCC cancer staging manual. 7th ed. New York: Springer, pp. 497-502.</citation>
  </reference>
  <reference>
    <citation>National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines for bladder cancer. www nccn org.</citation>
  </reference>
  <reference>
    <citation>Bellmunt J, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001 Sep;11(5):517-22. Review.</citation>
    <PMID>11493774</PMID>
  </reference>
  <reference>
    <citation>Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992 Jul;10(7):1066-73. Erratum in: J Clin Oncol 1993 Feb;11(2):384.</citation>
    <PMID>1607913</PMID>
  </reference>
  <reference>
    <citation>Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer &quot;unfit&quot; for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. Review.</citation>
    <PMID>21555688</PMID>
  </reference>
  <reference>
    <citation>De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10;30(2):191-9. doi: 10.1200/JCO.2011.37.3571. Epub 2011 Dec 12.</citation>
    <PMID>22162575</PMID>
  </reference>
  <reference>
    <citation>Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26.</citation>
    <PMID>17207911</PMID>
  </reference>
  <reference>
    <citation>Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.</citation>
    <PMID>26952546</PMID>
  </reference>
  <reference>
    <citation>Plimack ER, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33, 2015 (suppl;abstr 4502).</citation>
  </reference>
  <reference>
    <citation>Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.</citation>
    <PMID>27269937</PMID>
  </reference>
  <reference>
    <citation>Galsky M, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Presented at ESMO 2016 (abstract LBA31_PR).</citation>
  </reference>
  <reference>
    <citation>http://www.mercknewsroom.com/news-release/oncology-newsroom/mercks-keynote-045-studying-keytruda-pembrolizumab-advanced-bladder-c.</citation>
  </reference>
  <reference>
    <citation>Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8.</citation>
    <PMID>27939400</PMID>
  </reference>
  <reference>
    <citation>Balar A, et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Presented at ESMO 2016 (abstract LBA32_PR).</citation>
  </reference>
  <reference>
    <citation>Patel M. R., Ellerton J. A., Infante J. R., et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial. Journal of Clinical Oncology. 2017;35(supplement 6S) doi: 10.1200/JCO.2017.35.6_suppl.330. abstract 330.</citation>
  </reference>
  <reference>
    <citation>Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.</citation>
    <PMID>28375787</PMID>
  </reference>
  <reference>
    <citation>Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.</citation>
    <PMID>28373007</PMID>
  </reference>
  <reference>
    <citation>Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014 Jan;21(1):15-25. doi: 10.1038/cdd.2013.67. Epub 2013 Jun 21. Review.</citation>
    <PMID>23787994</PMID>
  </reference>
  <reference>
    <citation>Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.</citation>
    <PMID>22547592</PMID>
  </reference>
  <reference>
    <citation>Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.</citation>
    <PMID>22858559</PMID>
  </reference>
  <reference>
    <citation>Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017 Apr;17(4):515-523. doi: 10.1080/14712598.2017.1294156. Epub 2017 Feb 22. Review.</citation>
    <PMID>28274143</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

